Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 4 | 1 |
List of Figures | 5 | 1 |
Introduction | 6 | 1 |
Global Markets Direct Report Coverage | 6 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Overview | 7 | 1 |
Therapeutics Development | 8 | 3 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Stage of Development | 8 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Therapy Area | 9 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Indication | 10 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Pipeline Products Glance | 11 | 2 |
Late Stage Products | 11 | 1 |
Early Stage Products | 12 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Companies | 13 | 2 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Products under Development by Universities/Institutes | 15 | 2 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Therapeutics Assessment | 17 | 4 |
Assessment by Monotherapy/Combination Products | 17 | 1 |
Assessment by Mechanism of Action | 18 | 1 |
Assessment by Route of Administration | 19 | 1 |
Assessment by Molecule Type | 20 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Companies Involved in Therapeutics Development | 21 | 7 |
Amgen Inc. | 21 | 1 |
Bristol-Myers Squibb Company | 22 | 1 |
Chong Kun Dang Pharmaceutical Corp. | 23 | 1 |
Japan Tobacco Inc. | 24 | 1 |
Kowa Company, Ltd. | 25 | 1 |
Merck &Co., Inc. | 26 | 1 |
Pfizer Inc. | 27 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Drug Profiles | 28 | 13 |
AMG-899 Drug Profile | 28 | 2 |
anacetrapib Drug Profile | 30 | 2 |
BMS-795311 Drug Profile | 32 | 1 |
CKD-519 Drug Profile | 33 | 1 |
dalcetrapib Drug Profile | 34 | 4 |
HL-16 Drug Profile | 38 | 1 |
K-312 Drug Profile | 39 | 1 |
PF-04445597 Drug Profile | 40 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Dormant Projects | 41 | 1 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Discontinued Products | 42 | 3 |
Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) Featured News &Press Releases | 45 | 12 |
Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial | 45 | 1 |
Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics | 45 | 1 |
Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial | 46 | 2 |
Nov 13, 2015: Merck Provides Update on REVEAL Outcomes Study | 48 | 1 |
Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery | 48 | 1 |
Jun 03, 2015: Dezima Pharma s CETP Inhibitor, TA-8995, Phase 2b (TULIP) Study Results Published in The Lancet | 49 | 1 |
Jan 12, 2015: A World First - Discovery of a personalized therapy for cardiovascular disease | 50 | 1 |
Nov 13, 2014: Dezima Pharma Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects With Isolated, Elevated Lipoprotein(a) Levels | 50 | 1 |
Aug 29, 2014: Dezima Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia | 51 | 1 |
Jul 08, 2014: Dezima Pharma extends clinical development program for its CETP Inhibitor TA-8995 | 52 | 1 |
Jan 13, 2014: Dezima Pharma Completes Patient Enrolment for TULIP Phase 2B Study with CETP Inhibitor TA-8995 | 52 | 1 |
Aug 29, 2013: Dezima Pharma initiates Phase 2b TULIP study on CETP inhibitor program DEZ-001 | 53 | 1 |
Nov 05, 2012: Roche's Dalcetrapib Increases HDL Levels But Fails To Reduce Risk Of Cardiovascular Events, Study Finds | 54 | 1 |
Aug 26, 2012: Merck Provides Update On Anacetrapib Development Program | 55 | 1 |
May 07, 2012: Roche Provides Update On Phase III Study Of Dalcetrapib | 55 | 2 |
Appendix | 57 | 2 |
Methodology | 57 | 1 |
Coverage | 57 | 1 |
Secondary Research | 57 | 1 |
Primary Research | 57 | 1 |
Expert Panel Validation | 57 | 1 |
Contact Us | 57 | 1 |
Disclaimer | 58 | 1 |